Abla Adib A, Rekate Harold L, Wilson David A, Wait Scott D, Uschold Timothy D, Prenger Erin, Ng Yu-Tze, Nakaji Peter, Kerrigan John F
Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Childs Nerv Syst. 2011 Feb;27(2):265-77. doi: 10.1007/s00381-010-1250-7. Epub 2010 Aug 10.
This study aims to examine the outcomes of ten patients after orbitozygomatic (OZ) pterional surgery in cases of refractory epilepsy caused by hypothalamic hamartomas (HH).
Ten patients with HH and treatment-resistant epilepsy (mean age 18.3 years, range 0.7 to 42.7) underwent HH resection with an OZ approach (n = 8) or an OZ approach combined with a transventricular endoscopic approach (n = 2). Follow-up for the patients ranged from 0.5 to 6.2 years (mean 3.1). Outcomes were prospectively monitored with the use of a proprietary database.
Four patients (40%) are seizure-free, and four (40%) have had greater than 50% reduction in seizures. One patient had no significant change in seizure frequency, and one patient died unexpectedly 2.8 years after surgery. Six patients had total or near-total HH resection (98-100% of HH lesion volume). Of these, four of six (66%) were seizure-free, and two had at least greater than 50% reduction in seizures. Residual complications include diabetes insipidus (n = 1), poikilothermia (n = 1), visual field deficit (n = 1), and hemiparesis (n = 1). Eight families (80%) reported improved quality of life.
Patients with treatment-resistant epilepsy and tumors with an inferior or horizontal plane of attachment to the hypothalamus should continue to be approached from below. Those with both intrahypothalamic and parahypothalamic components may require approaches from above and below, either simultaneously or staged. For appropriately selected patients, the success of controlling seizures with an OZ is comparable to results utilizing transcallosal or transventricular approaches. The likelihood of controlling seizures appears to correlate with extent of resection.
本研究旨在探讨10例因下丘脑错构瘤(HH)导致难治性癫痫患者接受眶颧(OZ)翼点入路手术后的疗效。
10例HH合并药物难治性癫痫患者(平均年龄18.3岁,范围0.7至42.7岁)接受了HH切除术,其中8例采用OZ入路,2例采用OZ入路联合经脑室内镜入路。患者的随访时间为0.5至6.2年(平均3.1年)。通过使用专有数据库对疗效进行前瞻性监测。
4例患者(40%)无癫痫发作,4例(40%)癫痫发作减少超过50%。1例患者癫痫发作频率无显著变化,1例患者在术后2.8年意外死亡。6例患者实现了HH的全部或接近全部切除(切除了HH病变体积的98 - 100%)。其中,6例中的4例(66%)无癫痫发作,2例癫痫发作至少减少超过50%。残余并发症包括尿崩症(1例)、体温异常(1例)、视野缺损(1例)和偏瘫(1例)。8个家庭(80%)报告生活质量有所改善。
对于药物难治性癫痫且肿瘤附着于下丘脑下方或水平平面的患者,应继续采用经下途径。对于同时具有下丘脑内和下丘脑旁成分的患者,可能需要同时或分期采用上下联合途径。对于适当选择的患者,OZ入路控制癫痫发作的成功率与经胼胝体或经脑室入路的结果相当。癫痫发作得到控制的可能性似乎与切除范围相关。